{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:24:07Z","timestamp":1761823447849,"version":"build-2065373602"},"reference-count":32,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T00:00:00Z","timestamp":1323993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The treatment for prostate cancer patients with biochemical failure after local therapy remains controversial. Peripheral androgen blockade using a combination of a 5\u2010alpha reductase inhibitor and an antiandrogen may allow control of the prostate\u2010specific antigen (PSA). Because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>All patients had undergone previous definitive local therapy and had evidence of a rising PSA &gt;1ng\/mL, with no evidence of recurrent disease. Patients received both finasteride, 5 mg orally per day, and flutamide, 250 mg orally 3\u00d7 a day. Patients were followed for a PSA response and quality of life assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Ninety\u2010nine of 101 accrued patients were eligible. A \u226580% PSA decline was seen in 96 (96%) patients. The median time to PSA progression was 85 months. With a median follow\u2010up of 10 years, the median survival time had not been reached, and the 5\u2010year overall survival rate was 87%. Toxicity was mild, with 18 patients stopping for toxicity; 15 had diarrhea, 4 had gynecomastia, and 3 had transaminase elevation. Baseline Functional Assessment of Cancer Therapy Prostate Module and Treatment Outcome Index scores decreased by 5 points each at 6 months after enrollment.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The use of the finasteride\/flutamide combination is feasible, and results in PSA declines of \u226580% in 96% of patients with serologic progression after definitive local therapy. There were no unexpected toxicities, and the change in quality of life was mild. Further evaluation of this or a similar regimen in a controlled clinical trial is warranted. Cancer 2012. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26732","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T11:08:15Z","timestamp":1324033695000},"page":"4139-4147","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy"],"prefix":"10.1002","volume":"118","author":[{"given":"J. Paul","family":"Monk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Philips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Ahles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William K.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Cancer and Leukemia Group B","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,16]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(05)70163-4"},{"key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0094-0143(21)00925-3","article-title":"PSA after definitive radiotherapy for clinically localized prostate cancer","volume":"20","author":"Goad JR","year":"1993","journal-title":"Urol Clin North Am."},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1468"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.07.026"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.04.006"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.1949"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01867-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2497"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0923"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-71-6-1552"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030660"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908127"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36860-X"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00495-2"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80356-2"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66734-X"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00315-9"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh221"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00459-7"},{"key":"e_1_2_7_21_2","first-page":"194","volume-title":"Social functioning: sexual problems measures","author":"Sherbourne CD","year":"1992"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810083391504"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.9607"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1685"},{"issue":"7","key":"e_1_2_7_26_2","article-title":"A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/UK Intercontinental Trial CRUKE\/01\/013 [abstract]","volume":"29","author":"Klotz L","year":"2011","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36163-3"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.8.1566"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.037"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23473"},{"key":"e_1_2_7_32_2","unstructured":"CrookJM O'CallaghanCJ DingK et al.A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy. Paper presented at: ASCO Annual Meeting; June 4\u20108 2011; Chicago Ill."},{"journal-title":"BJU Int.","article-title":"The natural history of metastatic progression in men with prostate\u2010specific antigen recurrence after radical prostatectomy: long\u2010term follow\u2010up","author":"Antonarakis ES","key":"e_1_2_7_33_2"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26732","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:49:24Z","timestamp":1760284164000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26732"}},"subtitle":["Results of Cancer and Leukemia Group B (CALGB) 9782"],"short-title":[],"issued":{"date-parts":[[2011,12,16]]},"references-count":32,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/cncr.26732"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26732","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2011,12,16]]}}}